Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mifepristone and Mid-Trimester Termination of Pregnancy

This study has been completed.
Information provided by:
Boston University Identifier:
First received: September 28, 2006
Last updated: October 3, 2008
Last verified: October 2008

Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. The following day, the woman is admitted and given sequential doses of misoprostol until delivery occurs. The average length of time between the first dose of misoprostol and delivery is 12 hours, requiring most women to stay overnight. This is a randomized, placebo-controlled, double-blinded study designed to determine whether adding mifepristone significantly reduces the induction interval time (time between starting the first misoprostol and delivery) required for a second trimester termination.

Condition Intervention
Abortion, Induced
Abortion, Second Trimester
Drug: Addition of mifepristone 200 mg 24 hours before induction

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy

Resource links provided by NLM:

Further study details as provided by Boston University:

Primary Outcome Measures:
  • Time from start of induction to fetal delivery

Estimated Enrollment: 64
Study Start Date: March 2005
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   16 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 16 years of age or over
  • able to give informed consent in English or Spanish
  • Requesting termination of pregnancy

Exclusion Criteria:

  • Under 16 years of age
  • rupture membranes or intrauterine death
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00382538

United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Boston University
Principal Investigator: Lynn Borgatta, MD, MPH Boston University
  More Information

No publications provided by Boston University

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00382538     History of Changes
Other Study ID Numbers: 24597
Study First Received: September 28, 2006
Last Updated: October 3, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Boston University:
injection, intra-amniotic

Additional relevant MeSH terms:
Abortifacient Agents
Abortifacient Agents, Steroidal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 20, 2014